Canada grants patent on IGC-AD1, an investigational oral therapy for agitation in Alzheimer’s disease. Agitation is one of the hardest symptoms for families to manage.
POTOMAC, Md. – November 05, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company advancing Alzheimer’s disease therapeutics and Artificial Intelligence (AI) enabled healthcare technologies, today announced that the Canadian Intellectual Property Office granted Canadian Patent No. 3,095,729, “Method and Composition for Treating CNS Disorders”.
The patent covers the composition of IGC-AD1, an investigational oral therapy for agitation in Alzheimer’s.
With this grant, IGC-AD1 is protected by issued patents from the same patent family in all three North American markets: the United States (U.S. Patent No. 12,465,589), Canada, and Mexico (Mexican Patent No. 409,414). In total, IGC-AD1 is protected by 5 granted patents, with 10 more applications pending worldwide.
“Strong patent protection is central to our strategy for IGC-AD1,” said Ram Mukunda, CEO of IGC Pharma. “These patents strengthen our intellectual property portfolio. Our vision is to combine compelling clinical evidence with patent protection that supports long-term commercial value and helps attract major pharmaceutical partners to advance development and, if approved, expand patient access.”
IGC-AD1 is being evaluated in CALMA, a randomized, double-blind, placebo-controlled Phase 2 trial for agitation in Alzheimer’s dementia. CALMA completed enrollment in September 2026 and is in its final dosing period. Topline results will follow database lock and unblinding.
Agitation affects a large share of people living with Alzheimer’s disease and is one of the hardest parts of the disease for families and caregivers to manage. IGC-AD1 is an investigational oral liquid designed to address multiple biological mechanisms implicated in agitation, including neuroinflammation, CB1 receptor signaling, and neurotransmitter regulation.
About IGC Pharma, Inc.
IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer’s dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. Supported by its patent portfolio and commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding completion of dosing and patient follow-up in the Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s dementia; the timing of database lock, unblinding, topline analysis, and reporting of results; potential further clinical development and regulatory submissions; and the Company’s patent protection and partnering plans. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including delays in trial completion, data collection, verification, and analysis; uncertainties regarding the safety and efficacy of IGC-AD1 and whether CALMA will meet its endpoints; the need for additional clinical trials and regulatory review; financing needs; risks that issued patents may be challenged, narrowed, or circumvented; and other factors discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-KT and Quarterly Reports on Form 10-Q. There can be no assurance regarding the timing or outcome of the CALMA trial, regulatory approval, commercialization, or any pharmaceutical partnership. IGC-AD1 is investigational and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority. The Company undertakes no obligation to update forward-looking statements except as required by law.
Investor Relations Contact Andres Sanchez / Investor Relations
+1 301-983-0998 / +1 (202) 569-2566
[email protected]
Media: Kiran Mukunda, [email protected]
Recent Press Releases
IGC Pharma Unveils PRISM™ AI Platform to Move Alzheimer’s Risk Prediction to Brain-Health Action and Commercial Deployment
October 13, 2026
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026
September 28, 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $6.00, Citing CALMA Progress and Q4 2026 Topline Catalyst
August 28, 2026
Subscribe to Our Newsletter
Subscribe to get our latest content by email.
Subscribe
-
Potomac, MD, USA
COMPANY
FINANCIALS
TRADING & DATA
GDPR Cookie Banner
This website uses cookies and similar tracking technologies to enhance your browsing experience, analyze site traffic, provide personalized content, and support marketing activities. These technologies may involve the collection and processing of personal data, including through third-party services.
You can manage your preferences at any time through our cookie settings panel.
Accept All Reject All Settings
Close GDPR Cookie Settings

- Privacy Overview
- Necessary Cookies
- Google Analytics & Performance
- Marketing
- Cookie Policy
Powered by GDPR Cookie Compliance (opens in a new tab)
Privacy Overview
This website uses cookies and similar tracking technologies to enhance your browsing experience, analyze site traffic, provide personalized content, and support marketing activities. These technologies may involve the collection and processing of personal data, including through third-party services.
In accordance with applicable privacy laws, including the California Consumer Privacy Act (CCPA) and other relevant regulations, you have the right to accept, reject, or customize the use of non-essential cookies, as well as to opt out of the sale or sharing of your personal information for targeted advertising.
You can manage your preferences at any time through our cookie settings panel.
Necessary Cookies
These cookies are essential for the proper functioning, security, and accessibility of the website. They include functionalities such as session management, security controls, and storage of your privacy preferences.
- These cookies do not require user consent.
- They do not store personally identifiable information for tracking purposes.
Without these cookies, the website cannot function correctly.
Enabled Disabled
Google Analytics & Performance
We use analytics tools such as Google Analytics (cookies: _ga, _gid) to collect information about how users interact with the website (e.g., pages visited, time spent, navigation patterns).
- Purpose: Measure and improve website performance and usability.
- Data may be transferred to third parties (e.g., Google).
- These cookies may enable cross-site tracking and behavioral analysis.
These cookies are only activated with your explicit consent (opt-in). You may disable them at any time via the settings panel.
Enabled Disabled
Marketing
We use marketing and advertising technologies, including:
- Meta/Facebook Pixel (cookie: _fbp)
- Google DoubleClick / Google Ads services
- HubSpot tracking cookie (cookie: _hubspotutk)
- Pixelyoursite: (pys_fb_pixel_traffic_source)
These cookies and pixels allow us to:
- Deliver personalized advertisements.
- Measure campaign effectiveness.
- Track user interactions across websites (profiling).
Key considerations:
- They may involve data sharing with third-party platforms.
- They enable cross-site tracking and user profiling.
- They are subject to strict regulatory requirements and require explicit prior consent (opt-in).
You may opt out of these cookies at any time. Disabling them will not affect core site functionality but may limit personalized experiences.
Third-Party Integrations and External Services
Our website integrates services provided by third parties, including but not limited to:
- Analytics & Advertising: Google Analytics, Google Tag Manager, DoubleClick
- Marketing & CRM: HubSpot, ConvertKit, Mailchimp
- User Experience & Tracking: Hotjar
- Social Media Integrations: Facebook, Reddit
- Accessibility Services: Userway
These services may:
- Process personal data outside of our direct control.
- Transfer information to external jurisdictions.
- Introduce third-party dependencies and potential security risks.
We ensure that:
- Each integration is assessed based on necessity and proportionality.
- Vendors are evaluated under Third-Party Risk Management practices.
- Security measures such as Content Security Policy (CSP) are implemented to restrict unauthorized domains.
Your Privacy Rights
Depending on your jurisdiction, you may have the right to:
- Access, correct, or delete your personal data.
- Opt out of the sale or sharing of your data.
- Withdraw consent for non-essential cookies at any time.
To exercise these rights, please use the cookie management tool available on this site or contact us directly.
Enabled Disabled
Cookie Policy
To access further regulatory disclosures concerning our Cookie Policy , tracking mechanisms, and corporate data governance,. You will find definitive guidance on how to audit, restrict, or remove these cookies through your enterprise web browser settings.
Enable All Reject All Save Changes













































































